Results 1 to 10 of about 108 (87)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study

Rheumatology and Therapy, 2023
Introduction We studied the effect of intravenous (IV)-golimumab on fatigue and the association of fatigue improvement with clinical response post hoc in adults with active ankylosing spondylitis (AS) in the GO-ALIVE trial.
Atul Deodhar, Natalie J Shiff, Cinty Gong   +2 more
exaly   +5 more sources

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study

Rheumatology and Therapy, 2023
Introduction To assess changes in the Patient-Reported Outcomes Measurement Information System (PROMIS®) outcomes related to social, mental, and physical well-being after approximately 1 year of intravenous (IV) golimumab or infliximab treatment in ...
Clifton O Bingham, Natalie J Shiff, Stephen Xu   +2 more
exaly   +4 more sources

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis [PDF]

Rheumatology, 2021
Abstract Objectives To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA). Methods Children aged 2 to <18 years with active pc-JIA despite MTX ...
Nicolino Ruperto, Hermine I Brunner, Daniel J Kingsbury   +2 more
exaly   +6 more sources

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study

BMC Rheumatology, 2023
Background Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators.
Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J. Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman, Jeffrey R. Curtis   +9 more
doaj   +3 more sources

Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry [PDF]

Clinical Rheumatology, 2022
Abstract Infliximab and golimumab are intravenously (IV) administered tumor necrosis factor inhibitors approved to treat moderate-to-severe rheumatoid arthritis (RA) with concomitant methotrexate. Owing to differences in biologic construct, patients with IV-infliximab treatment failure may benefit from switching to IV-golimumab.
John Tesser, Iris Lin, Natalie J Shiff
exaly   +4 more sources

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age [PDF]

Arthritis Research & Therapy, 2019
Objective To evaluate the safety and efficacy of intravenous golimumab + methotrexate (MTX) in patients with active rheumatoid arthritis (RA) aged
John Tesser, Shelly Kafka, Raphael J. DeHoratius, Stephen Xu, Elizabeth C. Hsia, Anthony Turkiewicz   +5 more
doaj   +3 more sources

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Arthritis Research & Therapy, 2022
Background Intravenous (IV) golimumab, a TNFi, is approved for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We analyzed pooled safety results from three phase 3 IV golimumab trials in these rheumatologic
M. Elaine Husni, Atul Deodhar, Sergio Schwartzman, Soumya D. Chakravarty, Elizabeth C. Hsia, Jocelyn H. Leu, Yiying Zhou, Kim H. Lo, Arthur Kavanaugh   +8 more
doaj   +3 more sources

Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis

Clinical Therapeutics, 2015
The use of intravenous golimumab (GLM-IV), in combination with methotrexate, was approved by the US Food and Drug Administration in July 2013 for the treatment of moderate to severe, active rheumatoid arthritis (RA). GLM-IV is available in 50-mg vials, and the prescribing information specifies a dosing regimen of 2 mg/kg at 0 and 4 weeks and then every
Brenna L Brady
exaly   +3 more sources

The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial [PDF]

Clinical Rheumatology, 2021
Abstract Introduction/objectives To evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA). Methods Patients were randomized to IV golimumab 2 mg/kg (n=241) at
Alexis Ogdie, Soumya D Chakravarty, Kim Hung Lo   +2 more
exaly   +3 more sources

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis [PDF]

Alimentary Pharmacology and Therapeutics, 2015
SummaryBackgroundTumour necrosis factor alpha (TNFα)‐antagonism effectively treats ulcerative colitis (UC). The golimumab clinical programme evaluated subcutaneous (SC) and intravenous (IV) induction, and SC maintenance regimens, in TNFα‐antagonist‐naïve patients with moderate‐to‐severe active UC despite conventional treatment.AimTo evaluate dose ...
Brian G Feagan, J Johanns, Peter R Gibson   +2 more
exaly   +3 more sources